MDoutlook® proudly continues our innovative initiative of syndicated research analyzing the clinical impact of new data presented at the 58th ASH Annual Meeting in San Diego. Supporting the entire cancer community and building on over 40 analyses covering ASH since 2008, this is our first report from the 2016 meeting.
This OncoPoll™ focuses on B-cell lymphomas. It covers the choice between Rituxan® and Gazyva® in the front line setting for different lymphomas and the use of Rituxan and Revlimid® in the maintenance setting.
Our analyses of the meeting impact on US oncologists this year ((study sample n=100, see graphic) compares the different impact of the conference on those who attended the conference versus those who learned about the news from other sources:
• Oncologists see the comparison of the anti-CD20 antibodies Rituxan and Gazyva, in combination with chemotherapy in the front line setting for follicular and diffuse large B-cell lymphomas, as important clinical developments
• Overall usage of Gazyva in the front-line setting is expected to rise at the expense of Rituxan
• Use of maintenance strategies, with Rituxan in mantle cell lymphoma and Revlimid in CLL, is expected to continue to rise in popularity for hematologic malignancies
• Attendance at the meeting is not necessary for this new information to impact clinical practices. While initial awareness of the information may be lower, upon learning about it, the physicians who did not attend are just as, if not more likely to change their practices to integrate the clinical improvements
Download your complimentary copy of our report MDoutlook OncoPoll report from ASH 2016 on NHL-B-Cell.
MDoutlook continues its commitment to all stakeholders involved in the management of cancer to provide actionable and timely insight. As in previous years, we work with Oncology Business Review to share this important research with the cancer community.
To discuss your oncology and disease intelligence needs, please contact us at [email protected] or +1.404.496.4136.